SciBase Holding AB (SE:SCIB)
:SCIB
SCIB Stock Chart & Stats
kr0.33
>-kr0.01(-1.65%)
At close: 4:00 PM EST
kr0.33
>-kr0.01(-1.65%)
Day’s Range― - ―
52-Week Rangekr0.17 - kr0.50
Previous CloseN/A
Volume1.41K
Average Volume (3M)318.73K
Market Cap
kr295.73M
Enterprise Valuekr124.12M
Total Cash (Recent Filing)kr22.60M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.25
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding828,365,200
10 Day Avg. Volume218,776
30 Day Avg. Volume318,725
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)18.68
Price to Sales (P/S)3.07
P/FCF Ratio-1.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.08
Revenue Forecast (FY)kr66.85M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthConsistent multi-year revenue growth from 9.5M to 40.5M (2020–2025) signals improving commercial traction for Nevisense. Durable installed-base expansion and rising procedure volumes support recurring consumable and service revenues, bolstering predictable top-line drivers over the medium term.
Strong Gross MarginsA ~67% gross margin in 2025 (27.1M on 40.5M revenue) indicates favorable unit economics for device sales and consumables. High product-level margins create structural room to invest in R&D and clinical adoption while supporting margin resilience as volume scales, assuming manufacturing and supply costs stay controlled.
Low Financial LeverageReported total debt fell to zero in 2025, reducing interest and covenant risk. Low leverage preserves financial flexibility, limiting near-term solvency pressure and allowing the company to prioritize commercial investment or selective fundraising strategies without heavy fixed financing obligations.
Bears Say
Large And Widening Operating LossesEBIT deteriorated to -85.2M in 2025 from -67.2M in 2024, reflecting steep operating spend relative to revenue. Persistently large and widening losses impair the path to profitability, increase reliance on external capital, and heighten execution risk if cost controls or revenue acceleration don't materialize.
Severe Negative Cash FlowOperating cash flow plunged to -84.6M in 2025, worsening from -57.4M in 2024, and free cash flow stayed deeply negative. Sustained cash burn creates structural funding needs, increases dilution or refinancing risk, and constrains the company's ability to self-fund commercialization or regulatory activities.
Compressed Equity BaseEquity fell from 36.7M to 6.7M year-over-year, markedly weakening the capital base. A compressed equity position reduces balance-sheet flexibility, increases vulnerability to adverse shocks, and makes future equity raises more dilutive or difficult, limiting strategic options for growth and investment.
SciBase Holding AB News
SCIB FAQ
What was SciBase Holding AB’s price range in the past 12 months?
SciBase Holding AB lowest stock price was kr0.17 and its highest was kr0.50 in the past 12 months.
What is SciBase Holding AB’s market cap?
SciBase Holding AB’s market cap is kr295.73M.
When is SciBase Holding AB’s upcoming earnings report date?
SciBase Holding AB’s upcoming earnings report date is May 07, 2026 which is in 39 days.
How were SciBase Holding AB’s earnings last quarter?
SciBase Holding AB released its earnings results on Mar 13, 2026. The company reported -kr0.051 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.051.
Is SciBase Holding AB overvalued?
According to Wall Street analysts SciBase Holding AB’s price is currently Overvalued.
Does SciBase Holding AB pay dividends?
SciBase Holding AB does not currently pay dividends.
What is SciBase Holding AB’s EPS estimate?
SciBase Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SciBase Holding AB have?
SciBase Holding AB has 828,365,200 shares outstanding.
What happened to SciBase Holding AB’s price movement after its last earnings report?
SciBase Holding AB reported an EPS of -kr0.051 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.597%.
Which hedge fund is a major shareholder of SciBase Holding AB?
Currently, no hedge funds are holding shares in SE:SCIB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SciBase Holding AB
SciBase Holding AB (SCIB) is a Swedish medical technology company that specializes in developing innovative diagnostic solutions for skin cancer detection and monitoring. The company operates primarily in the healthcare sector, focusing on non-invasive and effective diagnostic tools. Its core products leverage advanced technology, particularly electrical impedance spectroscopy, to provide dermatologists and healthcare providers with real-time information to aid in the diagnosis of skin lesions, ultimately enhancing patient outcomes.
Technical Analysis
Clinical Laserthermia Systems AB Class B
―
Luxbright AB
―
Arcoma AB
―
Neola Medical AB
―
Iconovo AB
―